Recent News

• 08.25.2025 - Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025
• 08.20.2025 - Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
• 08.17.2025 - Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
• 08.07.2025 - Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025
• 08.01.2025 - Ascentage Pharma to Participate in Evercore China Biotech Summit
• 07.23.2025 - Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025
• 07.17.2025 - Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement

Recent Filings

• 08.21.2025 - EX-99.1 EX-99.1
• 08.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.18.2025 - EX-99.1 EX-99.1
• 08.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.08.2025 - EX-99.1 EX-99.1
• 08.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.01.2025 - EX-99.1 EX-99.1
• 08.01.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]